Neoplasms

All Conditions

Symptoms and General Pathology

Heart and Blood Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Recurrence

Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck

Thromboembolism

Laryngeal Diseases

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Laryngeal Cancer

Hypopharyngeal Cancer

Metastatic Squamous Neck Cancer With Occult Primary

Platelet Aggregation Inhibitors

All Drugs and Chemicals

Antipyretics

Anti-Inflammatory Agents

Antirheumatic Agents

Fibrinolytic Agents

Analgesics

Antineoplastic Agents

Clopidogrel

Aspirin

Alvocidib

Purinergic P2Y Receptor Antagonists

Neurotransmitter Agents

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase Inhibitors

Enzyme Inhibitors

Growth Inhibitors

Protein Kinase Inhibitors

acetylsalicylic acid

alvocidib

clopidogrel bisulfate

Barbara A. Conley, MD

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or metastatic head and neck cancer.

OBJECTIVES:

* Determine the standard response rate (complete response and partial response) and duration of response in patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with flavopiridol.
* Determine the qualitative and quantitative toxic effects of this regimen in these patients.
* Determine the progression-free and overall survival of patients treated with this regimen.
* Determine the effects of anti-platelet agents, aspirin and clopidogrel bisulfate, on the pharmacology of flavopiridol in these patients.
* Determine the effects of prophylactic anticoagulation with anti-platelet agents, aspirin and clopidogrel bisulfate, on the incidence of flavopiridol-related thrombosis in these patients.

OUTLINE: Patients receive flavopiridol IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Patients also receive oral aspirin and clopidogrel bisulfate beginning on day 0 and continuing throughout the study.

Patients are followed until death.

PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 1-3 years.

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

National Cancer Institute (NCI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)

Spots Global Cancer Trial Database for clopidogrel bisulfate